Early use of darolutamide with ADT and docetaxel shows efficacy in mHSPC

“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.

In this video, Michael S. Cookson, MD, MMHC, discusses the background and notable findings of the study, “Darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer: overall survival and other outcomes of the phase 3 ARASENS trial,” which will be presented at the 2022 South Central Section of the AUA Annual Meeting in Coronado, California. professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is co-editor in chief of Urology Times.®